In a recent article on nextavenue by Sam Perkins, light is shed on how progress is being made in diagnosing FTD and other types of early-onset dementias, but misdiagnoses are still common. While FTD has gained attention from medical professionals and researchers in recent years, much is still needed to aid in reaching a diagnosis quickly, and treating it effectively. Read the entire article here.
About 100 times rarer than Parkinson’s, and often mistaken for it, progressive supranuclear palsy (PSP) afflicts fewer than 20,000 people in the U.S.—and two-thirds do not even know they have it. Yet this little-known brain disorder that killed comic actor Dudley Moore in 2002 is quietly becoming a gateway for research that could lead to powerful therapies for a range of intractable neurodegenerative conditions including Alzheimer’s and chronic traumatic encephalopathy, a disorder linked to concussions and head trauma. Read the entire article here.
In a recent article on Huffington Post, written by Dr. Howard Fillit, Chief Science Officer of the Alzheimer’s Drug Discovery Foundation (ADDF), the importance of partnerships are explained in how they lead to the success of major initiatives such as TreatFTD – a new program designed to find drug treatments for FTD. In testing for FTD therapeutics, treatments could also be discovered for Alzheimer’s, ALS and other related neurodegenerative diseases. Read the entire article here.
Woody Durham, the longtime announcer for Tar Heel basketball and football games, recently shared with his fans that he has diagnosed with Primary Progressive Aphasia (PPA). “Last winter, I was diagnosed with a neurocognitive disorder that affects my language expression,” Durham wrote in explaining why he would no longer do any public speaking. He acknowledged the irony that, having made a 40-year career with his voice, his disease is defined as one that involves a loss of language facility. Read the entire article here.
In this article in Neurology Today, two scientists – Rosa Rademakers, PhD, and Bryan Traynor, MD, PhD – who started their careers studying very different diseases, ended up at the same genetic address and making a discovery that has changed conventional wisdom about two seemingly disparate conditions: frontotemporal degeneration (FTD) and amyotrophic lateral sclerosis (ALS). They discuss their separate efforts and findings here.